Statinele si hepatotoxicitatea – siguranta sau agresiune?

Abstract

Statins are among the most widely prescribed medications in the western world. This article discusses various aspects of statin hepatotoxicity including the safety of statins in patients with non-alcoholic fatty liver disease (NAFLD). The most common clinical hepatic manifestation of statins is asymptomatic elevation in aminotransferases and this appears to be a class effect of statins. In general the incidence of liver enzyme elevations in the statin treated patients has not been consistently different than in the placebo treated patients.